Summary & Overview
CPT 96401: Chemotherapy Administration, Subcutaneous or Intramuscular
CPT code 96401 covers the administration of non-hormonal anti-neoplastic chemotherapy by subcutaneous or intramuscular injection, a critical service in oncology practices nationwide. This code is widely recognized by major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, reflecting its importance in cancer treatment protocols. The publication provides a comprehensive overview of the clinical context for 96401, including its role in office-based chemotherapy administration and its relevance to hematology and oncology specialties. Readers will gain insight into payer coverage, typical sites of service, and related coding practices. The summary also highlights associated modifiers and taxonomies, as well as common ICD-10 diagnoses linked to this procedure, such as multiple myeloma in various stages. Additionally, the article outlines related CPT codes for comparison, offering a broader perspective on chemotherapy administration coding. This resource is designed to inform healthcare professionals, billing specialists, and policy analysts about the key aspects of 96401, supporting accurate reporting and understanding of its place in oncology care.
CPT Code Overview
CPT code 96401 is used to report the administration of chemotherapy via subcutaneous or intramuscular injection for non-hormonal anti-neoplastic agents. This procedure is a core component of oncology care, enabling the delivery of cancer treatment in a controlled clinical setting. The typical site of service for this code is the office, designated as Place of Service 11. Chemotherapy administration is essential for patients undergoing treatment for various malignancies, and accurate coding ensures proper documentation and reimbursement for these services.
Clinical & Coding Specifications
Clinical Context
A patient diagnosed with multiple myeloma, such as with diagnosis codes C90.00, C90.01, or C90.02, presents to the oncology office (Place of Service 11) for scheduled chemotherapy treatment. The provider, typically a hematology or oncology specialist, prepares and administers a non-hormonal anti-neoplastic agent via subcutaneous or intramuscular injection. The clinical workflow includes patient assessment, preparation of the chemotherapy drug, administration of the injection, and post-administration monitoring for adverse reactions. If a significant, separately identifiable evaluation and management service is performed on the same day, modifier 25 may be appended to the E/M code.
Coding Specifications
- Modifier
25: Used when a significant, separately identifiable evaluation and management service is performed on the same day as the chemotherapy administration. This modifier is appended to the E/M code, not the chemotherapy administration code.
| Provider Taxonomy Code | Specialty Name |
|---|---|
207RH0003X | Hematology & Oncology Physician |
207RX0202X | Medical Oncology Physician |
207ZP0102X | Pediatric Hematology-Oncology Physician |
These taxonomies represent providers specializing in hematology, oncology, medical oncology, and pediatric hematology-oncology, who are typically responsible for chemotherapy administration.
Related Diagnoses
-
C90.00- Multiple myeloma not having achieved remission- Indicates active disease requiring ongoing chemotherapy, relevant for administration of non-hormonal anti-neoplastic agents.
-
C90.01- Multiple myeloma in remission- Used for patients in remission who may still require maintenance chemotherapy.
-
C90.02- Multiple myeloma, in relapse- Indicates disease recurrence, often necessitating renewed chemotherapy treatment.
Each diagnosis code is clinically relevant to the use of 96401 for chemotherapy administration in patients with multiple myeloma.
Related CPT Codes
-
96402- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic- Used for administration of hormonal anti-neoplastic agents via the same routes. It is an alternative to
96401when the drug is hormonal.
- Used for administration of hormonal anti-neoplastic agents via the same routes. It is an alternative to
-
96372- Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular- Used for non-chemotherapy injections. Not typically billed with
96401unless a separate, non-chemotherapy injection is performed.
- Used for non-chemotherapy injections. Not typically billed with
-
96409- Chemotherapy administration; intravenous, push technique- Used for chemotherapy administered intravenously by push. May be used in the same patient on different days or as an alternative route.
-
96413- Chemotherapy administration; intravenous infusion, up to 1 hour- Used for chemotherapy administered intravenously by infusion. May be used in the same patient on different days or as an alternative route.
Codes 96409 and 96413 are commonly used as alternatives to 96401 when the route of administration is intravenous rather than subcutaneous or intramuscular.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT 96401 is $74.91, which is significantly lower than the BUCA (average commercial) mean rate of $107.25. Commercial payers such as Cigna and UnitedHealth Group have the highest mean rates, at $120.52 and $119.01 respectively, while Blue Cross Blue Shield and Aetna are closer to the BUCA average.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Medicare has the tightest range at $9.00, indicating less variability in rates. Cigna shows the widest dispersion at $65.50, reflecting greater variability in commercial reimbursement. Other commercial payers like UnitedHealth Group and Blue Cross Blue Shield also exhibit broader ranges compared to Medicare.
The table and chart below present a detailed breakdown of national mean rates and percentile values for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.